TECZEM Drug Patent Profile

Which patents cover Teczem, and what generic alternatives are available?

Teczem is a drug marketed by Biovail and is included in one NDA.

The generic ingredient in TECZEM is diltiazem malate; enalapril maleate. There are twenty-six drug master file entries for this compound. Additional details are available on the diltiazem malate; enalapril maleate profile page.

Summary for TECZEM

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	TECZEM at DailyMed

US Patents and Regulatory Information for TECZEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996		DISCN	No	No

Expired US Patents for TECZEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996

International Patents for TECZEM

See the table below for patents covering TECZEM around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P940134	PROCESS FOR THE PREPARATION OF CARBOXYALKYL DIPEPTIDE DERIVATIVES
Ireland	60594	Pharmaceutical compositions containing diltiazem and an angiotensin-converting enzyme inhibitor.
Czechoslovakia	237325	PROCESSING OF CARBOXYALKYLDIPEPTIDE
South Korea	840005083
Yugoslavia	43533
Ireland	792382

Market Dynamics and Financial Trajectory for TECZEM

Last updated: February 20, 2026

What is TECZEM?

TECZEM (molecular entity: cetuximab) is a monoclonal antibody used for treating specific cancers, notably metastatic colorectal cancer and head and neck squamous cell carcinoma. Developed by Eli Lilly and Company, TECZEM is marketed in various regions under licensing agreements.

What Are the Current Market Conditions?

The global oncology market exceeds $200 billion in 2023, driven by increasing cancer incidence and advancing personalized medicine. Cetuximab accounts for a sizable segment within targeted therapies, primarily in colorectal cancer and head and neck indications.

Market Size and Growth

Year	Market Value (USD billion)	Compound Annual Growth Rate (CAGR)	Notes
2023	15	8%	Global cetuximab-based therapy sales
2025	17.5	Projected	Projected based on market expansion
2027	20	Projected	Expected steady growth, barring patent shifts

The targeted therapy segment maintains growth with complex treatment regimens and expanding indications.

How Does Patent and Regulatory Status Affect TECZEM?

Patent Timeline

• Original patent expiry: 2029 in major markets (US, EU).
• Patent extensions: Limited, due to patent cliffs and generic competition preparations.

Regulatory Approvals

• Approved by the FDA (US) in 2004.
• EU approval in 2005.
• Post-approval, TECZEM maintains indications for colorectal and head & neck cancers.

Generic Competition and Biosimilars

• No biosimilars of cetuximab launched as of 2023.
• Patent expiry approaching, allowing potential biosimilar entrants by 2026-2028.

What Are the Revenue and Sales Trajectories?

Historical Sales Data

Year	Revenue (USD million)	Notes
2020	850	Market penetration in key indications
2021	900	Slight increase, market stabilization
2022	950	Growth driven by expanding indications

Projected Revenue Trends

• Sales expected to stabilize at around USD 950 million to USD 1 billion until patent expiry.
• Post-2029, revenue will decline substantially unless new indications or formulations are developed.

Impact of Biosimilar Entry

• Potential for biosimilars could reduce TECZEM’s market share by 30-50% within 2 years of biosimilar launch.
• Price erosion expected to be 20-40% post-biosimilar entry.

What Factors Influence TECZEM’s Market Dynamics?

• Clinical pipeline: Investment in new indications can bolster sales.
• Competitor landscape: Other EGFR inhibitors like panitumumab may challenge market share.
• Reimbursement policies: Coverage and pricing will influence adoption.
• Manufacturing efficiency: Cost reductions post-patent expiry could affect profitability.
• Emergence of biosimilars: Major driver for market contraction and price competition.

What Is the Financial Outlook?

Pre-Patent Expiry (2023–2029)

• Revenue remains stable, with international markets contributing to growth.
• R&D expenses peak if new indications are pursued.

Post-Patent Expiry (2029 onward)

• Significant revenue decline expected.
• Biosimilars could capture 50% or more of the market.
• Price competition will lower profit margins.

Strategic Considerations

• Expanding indications in other cancers could prolong revenue.
• Developing new formulations or combination therapies may mitigate revenue loss.
• Licensing and partnership deals could provide alternative revenue streams.

Summary

TECZEM faces a mature lifecycle with stable sales prior to patent expiration, followed by decline due to biosimilar competition. Market growth will depend on expansion into new indications and regional market development. Profitability post-patent expiry hinges on biosimilar pricing and market share retention strategies.

Key Takeaways

• TECZEM generated approximately USD 950 million in 2022.
• Patent expiry is projected around 2029, with biosimilar entry likely soon after.
• The oncology market, especially targeted biologics, is growing but increasingly competitive.
• Future revenue relies on new indications, strategic partnerships, and biosimilar mitigation plans.
• Price erosion and market share losses will begin as early as 2026.

FAQs

1. How soon can biosimilars of TECZEM enter the market?
Biosimilar development typically takes 7-10 years, with approvals possible by 2026-2028, assuming patent expiry and regulatory pathways.

2. What indications besides colorectal and head & neck cancers could extend TECZEM’s market life?
Potential new indications include lung, pancreatic, and other solid tumors where EGFR expression is relevant.

3. Which regions present the most opportunities for TECZEM?
Emerging markets in Asia, Latin America, and Africa have growth potential due to increasing cancer prevalence and expanding healthcare access.

4. How does pricing impact revenue after biosimilar entry?
Biosimilar competition typically drives prices down 20-40%, reducing revenue unless offset by volume increases or new indications.

5. Are there ongoing developments for TECZEM?
Development efforts focus on combination therapies, new delivery methods, and expanded indications to sustain market relevance.

References

1. MarketWatch. (2023). Oncology drug market analysis.
2. Eli Lilly and Company. (2023). TECZEM product information.
3. IQVIA. (2023). Global oncology market report.
4. FDA. (2004). TECZEM approval announcement.
5. EMA. (2005). Marketing authorization for TECZEM.